Recent Updates
Recently added Catalysts

AMG 732

Phase 2

Thyroid Eye Disease | Small molecule | Endocrine |Amgen Inc.|Last Updated: Aug 10, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials2
Total Enrollment124

FDA Designations

No designations recorded

Clinical trial landscape

AMG 732 · 2 trials · 1 indication

Phase 2 1Phase 1 1
NCT07438405An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye DiseaseThyroid Eye Disease
RECRUITING30 Analytics
PHASE2RECRUITING
An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease
Thyroid Eye Disease
NCT0743840530
Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants who are Proptosis Responders in the Trial Eye at Week 24 in Participants with TED who are Defined as Primary Nonresponders or Relapsed During the Safety Follow-up in the Parent Trial
Week 24

Responders are defined as participants with a ≥ 2 mm reduction from baseline in the trial eye without deterioration (≥ 2 mm increase) of proptosis in the fellow eye.

Part A: Number of Participants With Treatment-emergent Adverse Events
Day 1 through Week 36 (End of Study)
Part B: Change from Baseline in Proptosis Measurement by an Exophthalmometer in the Study Eye
Baseline to End of Treatment (EoT) (approximately 6 Months)

Secondary Endpoints

Change from Baseline at Week 24 in Proptosis Measurement by an Exophthalmometer in the Trial Eye in Participants with TED who are Defined as Primary Nonresponders or Relapsed During the Safety Follow-up in the Parent Trial
Baseline and Week 24
Number of Participants who are Proptosis Responders in the Trial Eye at Week 24 in Participants with TED who had Relapse after Achieving Proptosis Response in the Parent Trial
Week 24
Change from Baseline at Week 24 in Proptosis Measurement by an Exophthalmometer in the Trial Eye in Participants with TED who had Relapse after Achieving Proptosis Response in the Parent Trial
Baseline and Week 24
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
AMG 732EXPERIMENTALParticipants will receive AMG 732 subcutaneously (SC)
Part A: AMG 732EXPERIMENTALParticipants in 6 cohorts will receive either AMG 732 or placebo in Single Ascending Doses (SAD).
Part A: PlaceboPLACEBO_COMPARATORParticipants in 6 cohorts will receive either AMG 732 or placebo in Single Ascending Doses (SAD).
Part B: AMG 732 Low DoseEXPERIMENTALParticipants will receive AMG 732 low dose SC.
Part B: AMG 732 Medium DoseEXPERIMENTALParticipants will receive AMG 732 medium dose SC.
Part B: AMG 732 High DoseEXPERIMENTALParticipants will receive AMG 732 high dose SC.
Part B: PlaceboPLACEBO_COMPARATORParticipants will receive placebo SC.

Interventions

NameTypeDescription
AMG 732DRUGAMG 732 will be administered SC.
PlaceboOTHERSC injection
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 99 Years
SexALL
Healthy VolunteersNo
Study Sites8

Inclusion Criteria 1. Signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. 2. Age ≥ 18 years at the time of signing informed consent for parent trial. 3. Moderate-to-severe TED at the time of enrollm...

Countries:United StatesPolandSpainTaiwanAustraliaCanadaFranceGermanyGreeceItalyJapanSingapore
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

MEDIUMAug 11, 2026NCT06401044Status: RECRUITING → ACTIVE_NOT_RECRUITING
MEDIUMAug 11, 2026NCT06401044Status: RECRUITING → ACTIVE_NOT_RECRUITING
MEDIUMAug 11, 2026NCT06401044Status: RECRUITING → ACTIVE_NOT_RECRUITING
LOWJul 24, 2026NCT07438405lastUpdatePostDate: changed
LOWJul 24, 2026NCT07438405lastUpdatePostDate: changed
LOWJul 10, 2026NCT06401044lastUpdatePostDate: changed
LOWJul 10, 2026NCT06401044lastUpdatePostDate: changed
LOWJul 2, 2026NCT06401044lastUpdatePostDate: changed
LOWJul 2, 2026NCT06401044lastUpdatePostDate: changed
LOWJun 26, 2026NCT07438405lastUpdatePostDate: changed
LOWJun 26, 2026NCT07438405lastUpdatePostDate: changed
LOWJun 18, 2026NCT07438405lastUpdatePostDate: changed
LOWJun 18, 2026NCT07438405lastUpdatePostDate: changed
LOWJun 18, 2026NCT07438405lastUpdatePostDate: changed
LOWJun 12, 2026NCT06401044lastUpdatePostDate: changed
LOWJun 12, 2026NCT06401044lastUpdatePostDate: changed

Frequently asked questions about AMG 732

What is AMG 732 used for?

AMG 732 is an investigational small molecule being developed for the treatment of Thyroid Eye Disease. It is currently in Phase 2 clinical development and is not yet approved by the FDA. The drug is being studied in adults aged 18 years and older.

Who makes AMG 732?

AMG 732 is being developed by Amgen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AMGN. The company is conducting clinical trials to evaluate the drug's safety and efficacy in participants with Thyroid Eye Disease.

What phase is AMG 732 in?

AMG 732 is in Phase 2 clinical development for Thyroid Eye Disease. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 2 program includes a rollover trial that is currently recruiting participants.

What clinical trials is AMG 732 in?

AMG 732 is being studied in two clinical trials. NCT06401044 is a Phase 1 study in healthy participants and those with Thyroid Eye Disease, which is active but not recruiting. NCT07438405 is a Phase 2 open-label rollover trial evaluating efficacy and safety, which is currently recruiting.

Is AMG 732 a randomized, double-blind trial?

The clinical development program for AMG 732 includes randomized, double-blind, placebo-controlled trials. The Phase 1 study (NCT06401044) enrolls healthy volunteers and participants with Thyroid Eye Disease, while the Phase 2 rollover trial (NCT07438405) is open-label and recruiting participants.